RESEARCH PAPER
Interleukin 2 as a potential cancer marker in patients after kidney transplantation
 
More details
Hide details
1
Department of Internal Medicine, Diabetology and Nephrology, Medical University of Silesia, Zabrze, Poland
2
Department of Molecular Biology, Medical University of Silesia, Sosnowiec, Poland
3
Division of Statistics, Medical University of Silesia, Sosnowiec, Poland
4
Internal Practice, Bytom, Poland
 
Ann Agric Environ Med. 2015;22(2):320–324
KEYWORDS
ABSTRACT
Introduction:
Transplant recipients have a significantly greater incidence of cancer, compared with the general population, who are referred to immunosuppressive therapy as an additional malignancy risk factor. Therefore, there is a need to search for an easy in clinical practice neoplasm predictor, especially for this group of patients.

Material and Methods:
A group of 74 (43M and 31F; aged 46.8 ± 12 years) kidney transplant recipients was investigated in a three-year follow-up study. During the time of observation, 7 patients were diagnosed with neoplasm (7.4 ± 1.5 years after transplantation). A serum level of IL2 (ELISA test) and mRNA level of IL1beta, IL10 and TNFalfa in peripheral mononuclear blood cells – PBMCs (QRT – PCR method) were measured in every year of observation. Analysis of variances and t-Student test were used in groups mean comparison: N – patients developing malignant neoplasm group (24 probes); M – set of probes from patients with malignancies at the moment of diagnosis (11 probes); P – set of probes from patients before developing malignant neoplasm (10 probes); C – control group of healthy transplant recipients (31 probes).

Results:
Among the analyzed agents, only serum IL2 level differed between the analyzed groups, with higher values in the M compared with the P group (p<0.05) and with C group (p<0.01). There were no differences neither between N and C or P and C groups (p = 0.98), nor any correlation between IL2 and IL1b, IL2 and TNFalfa.

Conclusions:
The results may indicate that IL2 serum level might be consider as a useful late unspecific cancer marker, although larger studies should yield verification of this finding.

 
REFERENCES (20)
1.
Alberu J. Clinical insights for cancer outcomes in renal transplant patients. Transplant Proc. 2010; 42(9 Suppl): S36–40.
 
2.
Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant. 2001; 16(8): 1545–1549.
 
3.
Buell JF, Gross TG, ES. Woodle, Malignancy after transplantation. Transplantation 2005; 80(2 Suppl): S254–264.
 
4.
Webster AC, et al. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant. 2007; 7(9): 2140–2151.
 
5.
Kasiske BL, et al. Cancer after kidney transplantation in the United States. Am J Transplant. 2004; 4(6): 905–913.
 
6.
First MR, Peddi VR. Malignancies complicating organ transplantation. Transplant Proc. 1998; 30(6): 2768–2770.
 
7.
Koehl GE, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77(9): 1319–1326.
 
8.
Antony GK, Dudek AZ. Interleukin 2 in cancer therapy. Curr Med Chem. 2010; 17(29): 3297–3302.
 
9.
Zhang J, et al. Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers. J Exp Med. 1999; 190(9): 1297–1308.
 
10.
Lotze MT, et al. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1981; 41(11 Pt 1): 4420–4425.
 
11.
Strausser JL, et al. Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens. J Immunol. 1981; 127(1): 266–271.
 
12.
Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011; 7(5): 651–658.
 
13.
Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007; 117(5): 1175–1183.
 
14.
Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441(7092): 431–436.
 
15.
Maloy KJ, et al. CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med. 2003; 197(1): 111–119.
 
16.
Park SJ, et al. Impact of IL2 and IL2RB genetic polymorphisms in kidney transplantation. Transplant Proc. 2011; 43(6): 2383–2387.
 
17.
van den Hoogen MW, Hilbrands LB. Use of monoclonal antibodies in renal transplantation. Immunotherapy 2011; 3(7): 871–880.
 
18.
Mathan A, Kuruvilla S, Abraham G. Interleukin 2 receptor expression in renal biopsies and the diagnosis of acute allograft rejection. Indian J Pathol Microbiol. 2006; 49(1): 12–16.
 
19.
Numerof RP, Aronson FR, Mier JW. IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. J Immunol. 1988; 141(12): 4250–7425.
 
20.
Nedwin GE, et al. Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. J Immunol. 1985; 135(4): 2492–2497.
 
eISSN:1898-2263
ISSN:1232-1966